Immuron to Receive $2.16M R&D Tax Concession Refund
24 janv. 2018 09h30 HE
|
Immuron Limited
Melbourne, Australia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to announce that under the Australian Government’s Research and Development...
CEO to Present on US Investor TV Show and at Biotech Conference
10 janv. 2018 09h00 HE
|
Immuron Limited
MELBOURNE, Australia, Jan. 10, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to advise investors that CEO Dr Jerry Kanellos, was interviewed on The...
Immuron to Present at RedChip’s Global Online Growth Conference
06 déc. 2017 09h04 HE
|
Immuron Limited
MELBOURNE, Australia, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) wishes to advise investors that CEO Dr Jerry Kanellos is scheduled to present at...
Van Leeuwenhoeck Institute Updates Immuron Research Coverage
22 nov. 2017 09h00 HE
|
Immuron Limited
MELBOURNE, Australia, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (the “Company”) wishes to advise investors that Van Leeuwenhoeck Institute, a prominent European and US-based Life...
Immuron Granted US Patent for NASH Treatment
15 nov. 2017 09h00 HE
|
Immuron Limited
MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral...
Immuron Successfully Completes NASH Phase II Clinical Study Milestone
09 nov. 2017 09h00 HE
|
Immuron Limited
MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral...
Travelan Experiences Strong Q1 FY2018 Sales Growth
08 nov. 2017 09h00 HE
|
Immuron Limited
Key Highlights: Significant growth of sales for Immuron’s over-the-counter supplement Travelan® for Q1 2018 compared to Q1 2017 Travelan® US experienced a 197% increase in sales compared to Q1...
Immuron Ltd. Highlights Market Opportunity Following Recent Studies on Antibiotic Correlation to C. Difficile Infections
17 oct. 2017 08h53 HE
|
Immuron Limited
MELBOURNE, Australia, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral...
Immuron Highlights Recent Milestones in Quest to Effectively Treat Multiple Forms of Fatty Liver Diseases That Impact Millions
19 sept. 2017 08h00 HE
|
Immuron Limited
Company’s lead drug candidate IMM-124E is well-positioned to pioneer successful treatment for NASH and NAFLD, diseases for which there is no proven effective treatment Company provides overview of...
Immuron Commences US Non-Deal Institutional Investor Roadshow
15 août 2017 09h15 HE
|
Immuron Limited
MELBOURNE, Australia, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is pleased to release to shareholders and investors...